KaydedilenlerDerginizi ekleyin

Dergiler / The European Research Journal / 2021 / Cilt: 7 - Sayı: 5

The in vitro cytotoxic, genotoxic, oxidative damage potential of enoxaparin sodium in human peripheral blood mononuclear cells

Kadri YILDIZ
Sayfa
457–464
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusions: Enoxaparin sodium appeared to exhibit cytotoxic but not oxidative and genotoxic damage potentials in cultured human blood cells.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: Enoxaparin sodium, low-molecular weight heparin (LMWH) indicated for the prophylaxis deep vein thrombosis.
📊
Temel Bulgular & Veri:Methods: After exposure to different doses (from 0.5 to 100 mg/L) of enoxaparin sodium, cell viability was assessed by the cytotoxicity tests including MTT (3, (4,5-dimethylthiazol-2)-2,5-diphenyltetrazolium bromide) and lactate dehydrogenase (LDH) release assays.
💡
Sonuç & Katkı:Conclusions: Enoxaparin sodium appeared to exhibit cytotoxic but not oxidative and genotoxic damage potentials in cultured human blood cells.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:enoxaparin sodium · low-molecular-weight heparin · cytotoxicity

Abstract

Objectives: Enoxaparin sodium, low-molecular weight heparin (LMWH) indicated for the prophylaxis deep vein thrombosis. As far as we know, its cytotoxic, genotoxic and oxidative effects have never been studied on any cell lines. The purpose of the present study is to evaluate the in vitro cytotoxic, genotoxic damage potential and antioxidant/oxidant activity of enoxaparin sodium on primary human whole blood cultures. Methods: After exposure to different doses (from 0.5 to 100 mg/L) of enoxaparin sodium, cell viability was assessed by the cytotoxicity tests including MTT (3, (4,5-dimethylthiazol-2)-2,5-diphenyltetrazolium bromide) and lactate dehydrogenase (LDH) release assays. The antioxidant activity was measured by the total antioxidant capacity (TAC) and total oxidative stress (TOS) parameters. To determine the genotoxic damage potential, the rate of chromosomal aberrations (CAs) and 8-oxo-2'-deoxyguanosine (8-oxo-dG) levels were also assessed. Results: Cytotoxicity assays showed that treatment with enoxaparin sodium caused significant decreases in the cellular viability in a clear dose-dependent manner. Also, it was found that enoxaparin sodium did not alter the TAC and TOS levels. The genotoxicity assay showed that the formation of CAs was not observed in the lymphocytes. Likewise, the levels of 8-oxo-dG did not change in treated cultures as compared to control values. Conclusions: Enoxaparin sodium appeared to exhibit cytotoxic but not oxidative and genotoxic damage potentials in cultured human blood cells.

🔖

Bu Makaleye Atıf Yap

YILDIZ, K. (2021). The in vitro cytotoxic, genotoxic, oxidative damage potential of enoxaparin sodium in human peripheral blood mononuclear cells. The European Research Journal, Cilt: 7 - Sayı: 5, 457–464. https://ajindex.com/articles/403219

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Parakh RS, Sabath DE. Venous thromboembolism: role of the clinical laboratory in diagnosis and management. J Appl Lab Med 2019;3:870-82
  2. Akhtar F, Wan X, Wu G, Kesse S, Wang S, He S. Low-molecular-weight heparins: reduced size particulate systems for improved therapeutic outcomes. Molecules 2018;23:1757
  3. Nadi S, Vreugdenburg TD, Atukorale Y, Ma N, Maddern G, Rovers M. Safety and effectiveness of aspirin and enoxaparin for venous thromboembolism prophylaxis after total hip and knee arthroplasty: a systematic review. ANZ J Surg 2019;89:1204-10
  4. Jupalli A, Iqbal AM. Enoxaparin. In StatPearls [Internet]. StatPearls Publishing. 2020.
  5. Caprini JA, Arcelus J, Sehgal LR, Cohen EB, Reyna JJ. The use of low molecular weight heparins for the prevention of postoperative venous thromboembolism in general surgery. a survey of practice in the United States. Int Angiol 2002;21:78-85
  6. Tapson VF, Hyers TM, Waldo AL, Ballard DJ, Becker RC, Caprini J, et al. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med 2005;165:1458-64
  7. MacDougall DA, Feliu AL, Boccuzzi SJ, Lin J. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm 2006;63:5-15
  8. Tapson VF, Decousus H, Pin M, Chong BH, Froehlich JB, Monreal M, et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 2007;132:936-45
  9. Vats V, Nutescu EA, Theobald JC, Wojtynek JE, Schumock GT. Survey of hospitals for guidelines, policies, and protocols for anticoagulants. Am J Heal Pharm 2007;64:1203-8
  10. Haines ST, DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, et al. TED Pharmacotherapy. 5th Edition. Vol
  11. Chapter 26. Venous Thromboembolism. McGraw-Hill Global Education Holdings. LLC., 2002: pp. 373-413
  12. Fareed J, Leong W, Hoppensteadt D. Generic low-molecular-weight heparins: some practical considerations. Semin Thromb Hemost 2004;30:703-13
  13. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Anthithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e24S-e43S
  14. Fareed J, Fu K, Yang LH, Hoppensteadt DA. Pharmacokinetics of low molecular weight heparins in animal models. Semin Thromb Hemost 19